Background: The purpose of this study was to evaluate the in vitro activity of Akacid plus, a novel polymeric guanidine, compared to conventional antifungal drugs and chlorhexidine against 132 different fungal isolates Methods: Susceptibility testing was evaluated by determination of the minimal inhibitory concentration (MIC) in RPMI 1640 according to CLSI (Clinical and Laboratory Standards Institute) guidelines. The included clinical strains were: Candida species (n=90), dermatophytes (n=28), molds (n=14). Additionally, time killing-curves of Akacid plus were carried out on C. krusei ATCC 6258, C. tropicalis ATCC 750 and fluconazol-resistant C. albicans 4D. Results: MICs of Akacid plus against all strains of Candida spp. were in the range of 0.03-8 mg/l. MIC50 und MIC90 were equivalent against C. albicans and non-albicans species and reached values of 1 and 4 mg/l. MIC values of Akacid plus was comparable to that of nystatin, clotrimazole and caspofungin, whereas MIC90 (32 mg/l) of fluconazole and chlorhexidine was significantly higher than for Akacid plus. Akacid plus, chlorhexidine and fluconazole achieved corresponding MIC values (4-64 mg/l) against dermatophytes. The MIC range of Akacid plus, amphotericin B and voriconazole against tested moulds was 0.25-32 mg/l. Time-killing curves of Akacid plus against Candida spp. demonstrated fungicidal activity was at 1xMIC after exposure for 5-6 hours. Conclusions: Akacid plus showed fast fungicidal activity against Candida spp. and comparable in vitro effectiveness to conventional antifungal drugs and chlorhexidine.
Full conference title:
46th Interscience Conference on Antimicrobial Agents and Chemotherapy
- ICAAC 46th